With the technology advancements over the past decade, the treatment options for rheumatoid arthritis (RA) have expanded markedly. However, the acceptable duration for placebo control has also shortened, with rescue therapy typically offered within 14–16 weeks.
Both dynamic contrast-enhanced MRI (DCE-MRI) and RA MRI Score (RAMRIS) measures were equally sensitive to treatment effects with Infliximab.
Dexmedetomidine-ketamine combination is a safe alternative for sedation during the cardiac catheterization procedure without the incidence of any hemodynamic or respiratory effects. However, it is associated with some delayed recovery.
Management of children with congenital heart disease is challenging for anesthesiologists, especially during cardiac catheterization.
In patients with gout and major cardiovascular coexisting conditions, febuxostat was non-inferior to allopurinol with respect to rates of adverse cardiovascular events.
Gout is a chronic inflammatory disorder characterised by hyperuricemia, arthropathy, tophus development, and urolithiasis. Gout is reported to be associated with an increased risk of cardiovascular and chronic kidney disease.
Baricitinib alone or in combination with methotrexate, when used as initial therapyleads to a significant improvement in rheumatoid arthritis as compared to methotrexate alone.
Rheumatoid arthritis (RA) patients often suffer from number of restrictions in daily life due to frequent pain, fatigue, sleep disturbance and functional impairment in work and physical activities.
Radiographic findings including joint space narrowing and MRI detected bone marrow lesions, synovitis and effusion are significantly associated with the long term risk of total knee arthroplasty (TKA) in knee osteoarthritis patients.
Osteoarthritis (OA) is the most chronic joint disorder with an estimated prevalence of 15% worldwide, mainly affecting population aged between 56 to 84. Previous studies reported that aging and obesity were strongly associated with OA.
- 1 of 31